daunorubicin has been researched along with Acute Biphenotypic Leukemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhafiz, A; Elfishawi, S; Gameel, A; Ibraheem, D; Kamel, A; Madney, Y; Osman, R; Radwan, E; Rasekh, EO | 1 |
| Ali, OM; Baer, MR; Duong, VH; El Chaer, F; Emadi, A; Griffiths, EA; Koka, R; Law, JY; Lee, ST; Sausville, EA; Singh, ZN; Wong, J; Yared, JA | 1 |
| Karawajew, L; Ludwig, WD; Möricke, A; Ratei, R; Schabath, R; Schrappe, M; Zimmermann, M | 1 |
| Chi, HS; Choi, SJ; Im, HJ; Jang, S; Jun, KR; Lee, JH; Lee, KH; Moon, HN; Park, CJ; Seo, JJ | 1 |
1 trial(s) available for daunorubicin and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Infant; Leukemia, Biphenotypic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Analysis; Vincristine | 2013 |
3 other study(ies) available for daunorubicin and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Child; Child, Preschool; Cohort Studies; Cytarabine; Daunorubicin; Egypt; Etoposide; Female; Humans; Incidence; Induction Chemotherapy; Infant; Leukemia, Biphenotypic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Treatment Outcome; Young Adult | 2021 |
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.
Topics: Adult; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Combined Modality Therapy; Cytarabine; Dasatinib; Daunorubicin; Drug Substitution; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm, Residual; Neoplastic Stem Cells; Remission Induction | 2019 |
Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Child; Child, Preschool; Coloring Agents; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles; Treatment Outcome | 2007 |